EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 30 / No 5 (Mai 2014) Med Sci (Paris), 30 5 (2014) 551-557 References
Free Access
Issue
Med Sci (Paris)
Volume 30, Number 5, Mai 2014
Page(s) 551 - 557
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20143005019
Published online 13 June 2014
  1. Oleske J, Minnefor A, Cooper R, Jr, et al. Immune deficiency syndrome in children. JAMA 1983 ; 249 : 2345–2349. [CrossRef] [PubMed] [Google Scholar]
  2. Rubinstein A, Sicklick M, Gupta A, et al. Acquired immunodeficiency with reversed T4/T8 ratios in infants born to promiscuous and drug-addicted mothers. JAMA 1983 ; 249 : 2350–2356. [CrossRef] [PubMed] [Google Scholar]
  3. Rapport 2013 sur la prise en charge médicale des personnes vivant avec le VIH. Disponible à : http://www.sante.gouv.fr/IMG/pdf/Rapport_Morlat_2013_Mise_en_ligne.pdf [Google Scholar]
  4. Warszawski J, Tubiana R, Le Chenadec J, et al. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS french perinatal cohort. AIDS 2008 ; 22 : 289–299. [CrossRef] [PubMed] [Google Scholar]
  5. Frange P, Chaix ML, Veber F, Blanche S. Missed opportunities for HIV testing in pregnant women and children living in France. Pediatr Infect Dis J 2014 ; 33 : e60–e62. [CrossRef] [PubMed] [Google Scholar]
  6. Mayaux MJ, Burgard M, Teglas JP, et al. Neonatal characteristics in rapidly progressive perinatally acquired HIV-1 disease. The french pediatric HIV infection study group. JAMA 1996 ; 275 : 606–610. [CrossRef] [PubMed] [Google Scholar]
  7. Blanche S, Dollfus C, Faye A, et al. Pediatric aids, 30 years later. Arch Pediatr 2013 ; 20 : 890–896. [CrossRef] [PubMed] [Google Scholar]
  8. Brady MT, Oleske JM, Williams PL, et al. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART area. J Acquir Immune Defic Syndr 2010 ; 53 : 86–94. [CrossRef] [PubMed] [Google Scholar]
  9. Dollfus C, Le Chenadec J, Faye A, et al. Long-term outcomes in adolescents perinatally infected with HIV-1 and followed up since birth in the french perinatal cohort (EPF/ANRS CO10). Clin Infect Dis 2010 ; 51 : 214–224. [CrossRef] [PubMed] [Google Scholar]
  10. Héraud-Bousquet V, Lot F, Esvan M, et al. A three-source capture-recapture estimate of the number of new HIV diagnoses in children in France from 2003-2006 with multiple imputation of a variable of heterogeneous catchability. BMC Infect Dis 2012 ; 12 : 251. [CrossRef] [PubMed] [Google Scholar]
  11. Pursuing later treatment options II (PLATO II) project team for the collaboration of observational HIV epidemiological research Europe (COHERE), Castro H, Judd A, et al. Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet 2011 ; 377 : 1580–1587 [CrossRef] [PubMed] [Google Scholar]
  12. Sigaloff KC, Calis JC, Geelen SP, et al. HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review. Lancet Infect Dis 2011 ; 11 : 769–779. [CrossRef] [PubMed] [Google Scholar]
  13. Dejkhamron P, Unachak K, Aurpibul L, Sirisanthana V. Insulin resistance and lipid profiles in HIV-infected Thai children receiving lopinavir/ritonavir-based highly active antiretroviral therapy. J Pediatr Endocrinol Metab 2013 ; 21 : 1–10. [Google Scholar]
  14. Strehlau R, Coovadia A, Abrams EJ, et al. Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy. J Acquir Immune Defic Syndr 2012 ; 60 : 369–376. [CrossRef] [PubMed] [Google Scholar]
  15. Morén C, Noguera-Julian A, Garrabou G, et al. Mitochondrial evolution in HIV-infected children receiving first- or second-generation nucleoside analogues. J Acquir Immune Defic Syndr 2012 ; 60 : 111–116. [CrossRef] [PubMed] [Google Scholar]
  16. Saitoh A, Fenton T, Alvero C, et al. Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 2007 ; 5 : 4236–4242. [CrossRef] [Google Scholar]
  17. Payne BAI, Wilson IJ, Hateley CA, et al. Mitochondrial aging is accelerated by anti-retroviral therapy through the clonal expansion of mtDNA mutations. Nat Genet 2011 ; 43 : 806–810. [CrossRef] [PubMed] [Google Scholar]
  18. Purdy JB, Gafni RI, Reynolds JC, et al. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr 2008 ; 152 : 582–584. [CrossRef] [PubMed] [Google Scholar]
  19. Lambotte O. Les patients HIV controllers. Med Sci (Paris) 2012 ; 28 : 172–178. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  20. Warszawski J, Lechenadec J, Faye A, et al. Long-term nonprogression of HIV infection in children: evaluation of the ANRS prospective French pediatric cohort. Clin Infect Dis 2007 ; 45 : 785–794. [CrossRef] [PubMed] [Google Scholar]
  21. Sáez-Cirión A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013 ; 9 : e1003211. [CrossRef] [PubMed] [Google Scholar]
  22. Jain V, Hartogensis W, Bacchetti P, et al. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis 2013 ; 208 : 1202–1211. [CrossRef] [PubMed] [Google Scholar]
  23. Hocqueloux L, Avettand-Fènoël V, Jacquot S, et al. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother 2013 ; 68 : 1169–1178. [CrossRef] [PubMed] [Google Scholar]
  24. Persaud D, Palumbo PE, Ziemniak C, et al. Dynamics of the resting CD4(+) T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age. AIDS 2012 ; 26 : 1483–1490. [CrossRef] [PubMed] [Google Scholar]
  25. Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013 ; 369 : 1828–1835. [Google Scholar]
  26. Kent SJ, Reece JC, Petravic J, et al. The search for an HIV cure: tackling latent infection. Lancet Infect Dis 2013 ; 13 : 614–621. [CrossRef] [PubMed] [Google Scholar]
  27. Patel K, Van Dyke RB, Mittleman MA, et al. The impact of HAART on cardiomyopathy among children and adolescents perinatally infected with HIV-1. AIDS 2012 ; 26 : 2027–2037. [CrossRef] [PubMed] [Google Scholar]
  28. Purswani M, Patel K, Kopp JB, et al. Tenofovir treatment duration predicts proteinuria in a multiethnic United States cohort of children and adolescents with perinatal HIV-1 infection. Pediatr Infect Dis J 2013 ; 32 : 495–500. [CrossRef] [PubMed] [Google Scholar]
  29. Tudor-Williams G, Cahn P, Chokephaibulkit K, et al. Safety and efficacy of etravirine in HIV-1 infected, treatment-experienced children and adolescents (6 to < 18 years): week 24 primary analysis of the phase II PIANO study [abstract TULBPE027], 6th IAS Conference on HIV pathogenesis, treatment and prevention, Rome, 2011 ; pp. 17–20. [Google Scholar]
  30. Nachman S, Zheng N, Acosta EP, et al. Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. Clin Infect Dis 2014 ; 58 : 413–422. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.